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Abstract
Background: Human respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease in the
paediatic population, immunocompromised individuals and the elderly worldwide. However, despite global efforts
over the past several decades there are no commercially available vaccines. RSV encodes 2 non-structural proteins,
NS1 and NS2, that are type I interferon antagonists. RSV restricts type I interferon signaling and the expression of
antiviral genes by degrading STAT2. It has been proposed that NS1 binds to elongin C to form a ubiquitin ligase
(E3) complex that targets STAT2 for ubiquitination and proteosomal degradation.
Results: Here, we have engineered a live recombinant RSV in which the 3 consensus amino acids of the NS1
elongin C binding domain have been replaced with alanine (NS1F-ELCmut). Mutation of this region of NS1 resulted
in attenuation of RSV replication in A549 cells to levels similar to that observed when the NS1 gene is completely
deleted (ΔNS1). This mutation also resulted in moderate attenuation in Vero cells. Attenuation was correlated to
intracellular degradation of the mutated NS1 protein. Time course analysis showed that mutant NS1 protein
accumulated in cytoplasmic bodies that contained the lysosomal marker LAMP1. However lack of cleavage of LC3
suggested that autophagy was not involved. Induction of IFN-b mRNA expression also was observed in association
with the degradation of NS1 protein and attenuation of viral growth.
Conclusions: These results indicate that the elongin C binding region of NS1 is crucial for survival of the protein
and that disruption of this region results in the degradation of NS1 and restriction of RSV replication.
Keywords: RSV, NS1, attenuation
Background
Human respiratory syncytial virus (RSV) is the most
common cause of pediatric viral bronchiolitis and pneu-
monia in infants and young children worldwide, and
also causes severe respiratory infection in immunocom-
promised adults and the elderly [1,2]. Despite its world-
wide importance, and several decades of research, there
is still no vaccine or specific antiviral therapy for RSV
disease [3]. RSV has a single-stranded negative-sense
RNA genome, and belongs to the genus Pneumovirus of
the family Paramyxoviridae [1]. The RSV genome
encodes 11 proteins, including attachment and fusion
proteins G and F, nucleocapsid-associated proteins N, P
and L, transcription and RNA replication factors M2-1
and M2-2, the matrix M protein, small hydrophobic SH
protein, and two non-structural proteins NS1 and NS2.
The NS1 and NS2 proteins are dispensable for viral
replication in vitro. However, ablation of either NS pro-
tein, or both, significantly attenuates the growth of RSV
in vitro and in vivo [4-7].
Most viruses encode proteins that inhibit the innate
immune response to viral infection and promote virus
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human RSV are type I Interferon (IFN a/b)a n t a g o n i s t s
and target type I IFN induction and signaling [7,10-13].
Deletion of NS1, more so than NS2, from human
recombinant (r) RSV (rRSVΔNS1) attenuates replication
and results in an increase in the expression of type I
IFN-a/b and type III IFN-l, compared to wild-type (wt)
rRSV [7]. However, deletion of both NS proteins
(rRSVΔNS1/2) results in a greater induction of type I
and type III IFN expression and attenuates rRSV to a
greater extent than deletion of either single NS protein.
Deletion of NS1 and/or NS2 also attenuates rRSV in
Vero cells, which do not express type I IFN [6,7]. This
suggests that NS1 and NS2 have additional functions,
independent of the type I IFN response, that affect RSV
replication. One such function is the suppression of
early apoptosis (<18 h) in RSV-infected cells [14]. RSV
induces both pro- and anti-apoptotic factors in A549
and primary epithelial cells [15]. The NS proteins, both
individually and together, delay apoptosis and promote
viral replication via an IFN-independent pathway [14].
RSV NS1 and NS1/2 deletion mutants enhance matura-
tion of infected human dendritic cells, also suggesting
that NS1, and to a lesser extent NS2, suppress DC
maturation leading to a weakened immune response to
infection [16].
The mechanisms by which NS1 and NS2 suppress the
antiviral response are proving to be complex. RSV is
known to degrade STAT2, which is required for the
transcription of genes encoding a range of antiviral cel-
lular factors [17-20]. Recently, a mechanism by which
NS1 targets STAT2 for ubiquitination and proteasome-
mediated degradation has been proposed. Elliot et al.,
(2007), have identified consensus elongin C and cullin 2
binding sequences within NS1. They have described the
potential of NS1 to bind directly to elongin C and act as
an E3 ligase to target STAT2 to the proteasome for
degradation.
NS1/2 deletion mutants are being developed as live-
attenuated vaccine candidates. Preclinical studies in
chimpanzees demonstrated that both ΔNS1 and ΔNS2
deletion viruses were substantially attenuated in the
upper and lower respiratory tracts and induced signifi-
cant resistance to challenge with wild-type virus
[5,21,22]. Combination of the NS2 deletion with cold-
passaged (cp) and temperature-sensitive (ts) mutations,
resulting in the vaccine candidates rA2cpts248/404ΔNS2
and rA2cpts530/1009ΔNS2, proved to be overattenuat-
ing in seronegative children [3]. Evaluation of a ΔNS1
vaccine candidate is planned. However, virus that lacks
NS1 replicates less efficiently in vitro.I tw o u l db e
advantageous to identify residues in NS1 that are
involved in antagonising the IFN response, and if possi-
ble, to ablate these activities. To this end we sought to
develop and characterize a live rRSV containing modifi-
cation of one of the putative functional regions of NS1,
namely the proposed elongin C binding domain [19].
This domain (VxxLxxxCxxxK) in NS1 does not con-
form exactly with the consensus sequence (VxxLxxxCxxx
(A/I/L/V) of other elongin C-interacting proteins such as
VHL and SOCS 1-3 [23,24]. For this reason we chose to
modify only the 3 consensus residues (V, L and C) by
substitution with alanine (A). Here we demonstrate that
this region of NS1 is critical for the survival of the NS1
protein, and that rapid degradation of NS1 as a result of
this mutation correlates with viral attenuation in both
type I IFN-competent (A549) and -incompetent (Vero)
cells.
Materials and methods
Cells and virus stocks
Vero (African green monkey), HEp-2a (human epithe-
lial) and A549 (human type II alveolar epithelial) cells
were grown in Opti-MEM (Invitrogen) containing 5%
FBS (Sigma-Aldrich). Cells were incubated at 37°C in
5% CO2. Viral stocks were generated in Vero cells
infected at a MOI of 0.1 PFU/cell and harvested 7 days
later. The titre of viral stocks was determined by plaque
assay. Infected cells were incubated at 37°C for 7 days
under 0.8% methyl cellulose (Sigma) in OptiMEM with
2% FBS, and plaques visualized by immunostaining
using a goat anti-RSV polyclonal antibody (Virostat) fol-
lowed by horse-radish peroxidase-coupled anti-goat IgG
antibodies and DAB peroxidase substrate (Sigma) as
previously described [25].
Construction of NS1F, NS1F-ELCmut, ΔNS1 cDNA clones
Construction of a cDNA copy of the RSV genome under
the control of a T7 promotor has been described pre-
viously [26]. The full-length RSV cDNA used in the pre-
sent study was D46/6120, which is based on strain A2 and
contains a stabilizing 112 nt deletion of the downstream
non-coding region of SH as well as several silent muta-
tions in the last codons of the SH ORF [27,28]. The full-
length cDNA clone was not mutated directly, rather a
pGEM 7Z(+) plasmid containing the AatII-XbaI fragment
(leader, NS1, NS2 and part of the N genes) was generated
and used for site directed mutagenesis (Stratagene Quik-
change kit). A FLAG (Sigma) tag and diagnostic KpnI site
were introduced to the N-terminus of the NS1 ORF
directly following the start codon using the oligonucleo-
tide: 5’- GG TTA GAG ATG GAC TAC AAG GAC GAC
GAC GAC AAG GGT ACC GGC AGC AAT TC-3’
(FLAG tag in italics, KpnI site underlined). The putative
elongin C binding domain of NS1, also was mutated by
site directed mutagenesis. The 3 consensus amino acids of
the NS1 elongin C binding motif VxxLxxxC were mutated
to alanine using the oligonucleotide: 5’-G TTT GAC AAT
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TAT ACT G-3’ (alanine underlined). AatII-XbaI mutated
fragments, containing either the introduced FLAG tag
within NS1, or the FLAG tag and the alanine substitution
mutations, were introduced into the full-length antige-
nome cDNA D46/6120 using standard restriction enzyme
digestion and T4 ligase (New England Biolabs) according
to the manufacturer’s instructions. The mutated cDNA
clones were designated NS1F (FLAG tag) and NS1F-ELC-
mut (FLAG tag and alanine substitutions within the elon-
gin C binding domain), and sequenced to ensure the
presence of the mutations. A ΔNS1 cDNA clone, contain-
ing deletion of the NS1 open reading frame from D46/
6120, was also engineered, by excising the entire NS1
gene, including the gene start and gene end signals, follow-
ing the introduction of flanking PstI sites (Stratagene).
Recombinant RSV (rRSV) recovery
Mutated rRSVs were recovered using a modified trans-
fection protocol described previously [26,29]. Briefly,
75% subconfluent BSR T7/5 cells were transfected in 6-
well dishes simultaneously with 5 μgo fa n t i g e n o m e
plasmid (NS1F, NS1F-ELCmut or ΔNS1), 2 μge a c ho f
the support plasmids pTM1-N and pTM1-P, and 1 ug
each of pTM1-L and pTM1-M2-1. Transfections were
performed with Lipofectamine 2000 (Invitrogen) in
OptiMEM without serum at 37°C. After 1 day the trans-
fection medium was replaced with Glasgow’sm i n i m a l
essential medium (supplemented with 5% FBS and 1%
L-glutamine) and the cells were expanded. After a
further 4 days of incubation at 37°C, cell-medium mix-
tures were passaged onto fresh HEp-2a cells. Once cyto-
pathic effects indicative of RSV infection were observed
5-7 days later, cell-medium mixtures were harvested and
used to infect HEp-2a monolayers for three rounds of
plaque purification. A stock of each recovered virus was
then generated in Vero cells. The presence of the
expected mutations and the absence of other spurious
mutations were confirmed by RT-PCR and nucleotide
sequencing of viral genomic RNA for all rRSVs
generated.
Growth of rRSV in vitro
Quadruplicate cell culture monolayers of A549 and Vero
cells were infected with either wt RSV (D46/6120),
NS1F, NS1F-ELCmut, or ΔN S 1a taM O Io f0 . 0 1P F U /
cell. Cell culture supernatants were collected daily for 5
days and the virus titres determined by plaque assay.
Statistically significant differences in growth between
rRSVs was detected by ANOVA
Western Blot analysis
Triplicate cell monolayers were infected with either wt
RSV, NS1F or NS1F-ELCmut at a MOI of 1 PFU/cell,
or mock infected with media, and incubated at 37°C. At
24 h and 48 h p.i., cells were washed in PBS and lysed
with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM
N a C l ,1 %N P - 4 0 ,1 %s o d i u md e o x y c h o l a t e ,0 . 1 %S D S )
containing protease inhibitors (Pierce). 20 μgt o t a lp r o -
tein (BCA assay; Pierce) from each lysate was separated
through pre-cast 12% polyacrylamide Bis-Tris gels (Invi-
trogen). Proteins were then transferred to nitrocellulose
membranes and blocked in either 5% skim milk
(Diploma)/PBS or 1% BSA (Sigma)/PBS containing 0.1%
Tween 20. The blots were analysed using a goat anti-
RSV antiserum (Virostat), or a rabbit antiserum raised
against the C-terminal 13 amino acids of NS2, which
reacts with both NS1 and NS2, and FLAG was detected
using a mouse anti-FLAG IgG (Sigma). As a marker for
autophagy, LC3 was detected using an antibody against
LC3B (Cell Signaling Technology). b- a c t i nw a su s e da sa
loading standard and detected using a mouse anti-b-actin
IgG (Sigma). Bound antibodies were visualized with spe-
cies-specific IgG conjugated to either IR800 (Rockland
Inc), or HyLyte680 (AnaSpec) and a Li-Cor Odyssey
scanner. RSV protein expression was quantified using
Odyssey™ densitometry software and statistical differ-
ences identified using Students t-test.
RNA extraction and PCR
Cells were infected at a MOI of 1 with either NS1F,
NS1F-ELCmut, ΔNS1, or mock infected with media, and
harvested 24 h p.i., Total RNA was isolated using TRIzol
(Invitrogen) and the RNeasy total RNA isolation kit
(QIAGEN). RT-PCR was performed using RSV-specific
primers and the PCR products sequenced also using
RSV-specific primers. For quantitiative (q) PCR, RT was
performed with oligo (dT)20 primers (Invitrogen) to
select mRNA from the total RNA preparations. qPCR
was performed using dual-labeled probe and primer sets
as previously described [7] to quantify b-actin and IFN-b.
PCR primers and dual-labeled probes to quantify NS1
and N mRNA were designed using Primer 3 http://frodo.
wi.mit.edu/primer3/ software. qPCR was performed
using QuantiTect™ reagents (QIAGEN) and the Roto-
gene 3000 (Roche). The fold increase in target expression
compared to mock-infected was calculated using the
2
-ΔΔCt formula.
Immunofluorescence
Confluent monolayers of Vero cells were cultured on
coverslips and infected with either NS1F, NS1F-ELCmut
or ΔNS1 at a MOI of 1 PFU/cell, or mock infected with
media. At specific times, cells were fixed with 4% for-
maldehyde (ProSciTech) for 30 min and permeabilized
with 0.1% Triton X-100 for 10 min. Primary and sec-
ondary antibodies were diluted in 1% BSA/PBS. NS1
and other RSV proteins were detected using antiserum
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organelles were detected using monoclonal antibodies to
EEA, GM130, LAMP1 (BD Transduction Labs), and PDI
(Invitrogen). Secondary antibodies, anti-mouse and anti-
rabbit specific IgG were conjugated to Alexa Fluor 488
or 594 (Invitrogen). Following antibody incubation and
washes, coverslips were mounted on glass microscope
slides using ProLong Gold mounting medium (Invitro-
gen) and visualized using a Nikon Eclipse E3600 fluores-
cence microscope. Images were collated using adobe
Photoshop software. Statistical differences in protein
detection were identified using Student’s t test.
Results
Insertion of a FLAG tag and amino acid substitutions in
the NS1 protein of recombinant (r)RSV
For the present study, the wild-type (wt) rRSV construct
D46/6120, based on the A2 strain, was modified to
express a FLAG tag at the N-terminus of NS1 (NS1F;
Figure 1a). This was to allow differentiation between
NS1 and NS2, as the available NS-specific antiserum
does not differentiate between NS1 and NS2 [30].
Immunofluorescence of NS1F-infected Vero cells
demonstrated 100% co-localisation between FLAG and
NS1/NS2 (Figure 1b). The NS1F clone was then modi-
fied to replace the consensus residues of the elongin C
binding motif of NS1 with alanine residues (Figure 1c)
to generate the NS1F-ELCmut virus, which was
sequenced in its entirety and confirmed to contain the
alanine replacements (Figure 1d). We also generated a
ΔNS1 virus by first introducing PstI sites flanking NS1,
and then using the PstI sites, to delete the entire NS1
gene (Figure 1a).
Mutations in the elongin C binding motif reduced the
replication of rRSV in vitro
Single step growth curve experiments, performed over 5
days post-infection (p.i.), in both Vero and A549 cells,
demonstrated that the introduction of the FLAG tag to the
N-terminus of NS1 (NS1F) did not affect viral growth in
vitro compared to wt RSV (D46/6120; Figure 2a and 2b).
By day 3 p.i. in both A549 and Vero cells, there was no
NS1 NS2 NP S H M G
L
M2 F le
PstI
(37)
PstI
(589)
AatII
(19074)
XhoI
(4482)
XbaI
(1531)
(c)
SOCS1 VRPLQELC
SOCS3 VATLQHLC
VHL VYTLKERC
NS1 VALLKITC
Consensus VXXLXXXC
Mutationin AALAKITA
NS1
Regionofhomology
rRSVNS1F
rRSVNS1FͲELCmut
AALAKITA
VALLKITC
AntiͲFLAG AntiͲNS1/2 Overlay DAPI (b)
(a)
(d)
FLAG
Figure 1 Generation of rRSVs with a FLAG tag and mutations in NS1. (a) The full-length rRSV plasmid D46/6120 showing restriction enzyme
sites used to introduce mutations (see Materials and Methods) and the position of a FLAG tag (grey bar) introduced to the N-terminus of NS1
(NS1F virus). Le = leader region. (b) Recovered NS1F virus was analysed by immunofluorescence in Vero cells by dual labelling with anti-FLAG
monoclonal antibody (green) and anti-NS1/2 polyclonal antiserum (red). Nuclei were stained with DAPI and overlay images generated using
Photoshop. (c) The 3 consensus residues of the NS1 elongin C binding domain (underlined) were replaced with alanine and the resulting cDNA
was used to generate the NS1F-ELCmut virus. (d) Nucleotide substitutions (blue) that changed the 3 consensus residues to alanine in the
recovered NS1F-ELCmut virus.
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and wt RSV-infected cells. Replacement of the 3 consensus
residues within the elongin C binding motif of NS1 with
alanine residues resulted in attenuation of the virus in
comparison to both wt RSV and NS1F. In A549 cells,
NS1F-ELCmut was significantly restricted in growth by
180-fold compared to NS1F at 5 days pi (P < 0.01). Dele-
t i o no ft h ee n t i r eN S 1p r o t e i n( ΔNS1) also significantly
restricted growth as expected (P < 0.01). NS1F-ELCmut
appeared to be more attenuated than ΔNS1 in A549 cells
between days 0 and 3 pi, as the titre of shed virus was mar-
ginally significantly different (P < 0.05). However, given
that the viral titre on D0 was higher for ΔNS1 than for
NS1F-ELCmut, this is likely to not be biologically signifi-
cant. (Figure 2a). The ΔNS1 growth curve in A549 cells is
slightly atypical in that there is a reduction in shed virus
on days 4 and 5 p.i. This was observed in several indepen-
dent experiments (data not shown), and may be due to
antiviral responses dampening shed virus. In Vero cells,
NS1F-ELCmut replication was also significantly attenuated
compared to NS1F and wt RSV (P < 0.01) over the 5 days,
however, was less attenuated than in A549 cells, with a 20-
fold reduction by 5 days pi. Deletion of the entire NS1
(ΔNS1) restricted growth by a further 20-fold in Vero cells
(P < 0.01 compared to NS1F-ELCmut;Figure 2b).
Mutation within the elongin C binding motif reduced the
expression of NS1 protein
We investigated the possibility that the 3 alanine substi-
tutions within the elongin C binding motif of NS1 had
reduced the expression of NS1 using Western Blot ana-
lysis. The expression of NS1 in Vero cells infected with
NS1F-ELCmut was significantly reduced at 24 h and 48
h p.i. compared to cells infected with wt (D46/6120)
RSV (P < 0.001; Figure 3a and 3b). NS2 expression was
not affected by the mutations within the elongin C bind-
ing domain of NS1 (Figure 3a and 3b). The significant
reduction of NS1 expression by NS1F-ELCmut also was
observed by Western Blot when NS1 was detected using
the FLAG tag (Figure 3c, middle panel). The non-speci-
fic band detected on this blot (Figure 3c, middle panel)
is the same size as NS2, however appears in both mock-
infected and viral-infected samples and is therefore not
NS2. RSV infection in mock, NS1F and NS1F-ELCmut-
infected cells was detected using anti-RSV polyclonal
antibody (Figure 3c, upper panel). Quantification of N
protein expression demonstrated that the NS1F-ELCmut
virus was attenuated at 24 h and 48 h p.i. compared to
NS1F virus, although the differences in expression were
marginally significiant (P = 0.046; Figure 3d). In con-
trast, the expression of NS1 by the NS1F-ELCmut virus
compared to the NS1F virus was significantly reduced
(P = 0.005 at 24 h p.i., and 0.0034 at 48 h p.i.). This
indicated that for the NS1F-ELCmut virus, NS1 protein
expression was reduced more than would be expected
due to restriction of viral replication alone.
The mutations in the elongin C binding domain caused
NS1 to accumulate in cytoplasmic bodies
Western Blot analysis of infected cells indicated that the
NS1 expressed by NS1F-ELCmut was reduced, to unde-
tectable levels. The expression of NS1 protein over time
was investigated by immunofluorescence of Vero cells
infected with NS1F or NS1F-ELCmut (Figure 4). NS1 was
D0 D1 D2 D3 D4 D5
wtRSV
NS1F
NS1FͲELCmut
ȴNS1
(a) (b)
V
i
r
u
s

t
i
t
r
e

(
l
o
g
1
0
p
f
u
/
m
l
)
V
i
r
u
s

t
i
t
r
e

(
l
o
g
1
0
p
f
u
/
m
l
)
1
0
4
5
3
2
6
1
0
4
5
3
2
6
D0 D1 D2 D3 D4 D5
*
*
**
Figure 2 The growth kinetics of NS1-mutated viruses. Single step growth curves for the NS1F, NS1F-ELCmut and ΔNS1 viruses compared to
wt RSV in (a) A549 and (b) Vero cells. The cell supernatants of quadruplicate cultures were collected daily and viral titres were determined by
plaque assay. The mean titres (log10 pfu/ml) are shown with standard error. In A549 cells, NS1F-ELCmut and ΔNS1 were significiantly attenuated
in comparison to both NS1F and wt RSV (*P < 0.01). In Vero cells, NS1F-ELCmut was attenuated in comparison to NS1F and wt RSV (* P < 0.01),
and ΔNS1 was further attenuated in comparison with NS1F-ELCmut (** = P < 0.01).
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infected cells (<3% at any time p.i.). In Vero cells infected
with NS1F, NS1 was detected in both the cytoplasm and
nucleus from 15 h to 48 h p.i. Tracking of NS1 expression
over 48 h p.i. in cells infected with NS1F-ELCmut showed
that NS1 was detected in the nucleus at 15 h and 24 h p.i.,
b u tn o ta t3 2ho r4 8hp i .F r o m1 5hp . i . ,N S 1w a s
observed to accumulate in the cytoplasm as distinct bodies
(Figure 4, arrows). These data show that mutation within
the elongin C binding motif of NS1 dramatically alters its
cellular localization over time and induces the accumula-
tion of NS1 within cytoplasmic bodies. A549 cells also
were infected with NS1F and NS1F-ELCmut and stained
for immunofluorescence detection of NS1 over 48 h pi.
However, NS1 was not detected at any time in the NS1F-
ELCmut-infected A549 cells.
NS1F-ELCmut induced an increase in IFN-b induction
We investigated the potential correlation of viral
attenuation in A549 cells with an increase in the pro-
duction of type I interferon (IFN). We quantified the
levels of IFN-b, RSV N and RSV NS1 mRNA expression
in relation to b-actin in A549 cells infected with NS1F,
NS1F-ELCmut, or ΔNS1 at a MOI of 1 PFU/cell, or
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Figure 3 The effect of mutation on NS1 and NS2 expression. (a) Vero cells were infected with wt RSV, NS1F-ELCmut, or mock infected, and
cells were lysed in RIPA buffer 24 h and 48 h p.i. Equivalent amounts of protein for each sample were separated by SDS-PAGE and analysed by
Western blot using anti-NS1/2 polyclonal antiserum. Representative of three separate experiments. (b) Densitometric quantification of NS1 and
NS2 expression in comparison to b-actin for triplicate wt RSV and NS1F-ELCmut-infected Vero cell cultures. NS1F-ELCmut infected cells expressed
significantly less NS1 than wt RSV (* P < 0.001). NS2 expression was not different for the 2 viruses. (c) NS1F, NS1F-ELCmut and mock-infected cell
lysates were probed with anti-FLAG to detect tagged NS1 protein and anti-RSV polyclonal antiserum to detect other RSV proteins. Representative
of three separate experiments. (d) Densitometric quantification of NS1 and N expression in comparison to b-actin for triplicate NS1F and NS1F-
ELCmut-infected Vero cell cultures. Cells infected with NS1F-ELCmut expressed significantly less NS1 than cells infected with NS1F (* P < 0.05).
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Page 7 of 12mock infected and harvested 24 h p.i. (Figure 5). We
chose to investigate IFN-b mRNA expression and not
IFN-a mRNA expression, as previous studies have shown
than deletion of NS1 (ΔNS1) from rRSV has a greater
effect on IFN-b expression than IFN-a expression [7].
Expression of mRNA was quantified as a fold increase
compared to mock-infected cells. We found that IFN-b
mRNA was elevated in cells infected with either NS1F-
ELCmut or ΔNS1 compared to cells infected with NS1F
(Figure 5a). However, this increase was only marginally
statistically significant for NS1F-ELCmut (P = 0.038). In
contrast, the levels of N mRNA in cultures infected with
NS1F-ELCmut and ΔNS1F were greatly reduced com-
pared to NS1F, reflecting their attenuation. Given the
severe attenuation of NS1F-ELCmut and ΔNS1 in A549
cells, the amount of FN-b induction was interpreted rela-
tive to the level of viral replication, as represented by N
mRNA, in these cells. When the ratios of IFN-b/N
mRNA were compared, the rations for NS1F-ELCmut
and ΔNS1 were significantly (P <0 . 0 1 )g r e a t e rt h a nf o r
NS1F. The difference in IFN-b/N ratio between NS1F-
ELCmut and ΔNS1 was not significant (Figure 5c). We
also measured levels of NS1 mRNA (Figure 3d), and
observed significantly lower levels in NS1F-ELCmut-
infected A549 cells than in NS1F-infected A549 cells (P <
0.01), which correlated to differences in viral growth. We
also confirmed that NS1 mRNA was not expressed by
the ΔNS1 virus, as expected.
Mutations in the elongin C binding motif of NS1 resulted
in NS1 accumulation within lysosomes
We investigated the identity of the cytoplasmic bodies
containing the mutant NS1 using co-localisation of
antibodies to NS1/2 and other cellular organelle markers.
NS1 did not co-localise with the cis-golgi marker GM130
(golgi marker 130), the endoplasmic reticulum marker
PDI (protein disulfide isomerase), or the endosome mar-
ker EEA (early endosome antigen 1). Co-localisation was
observed with lysosome-association membrane protein 1
(LAMP1), a marker for lysosomes (Figure 6). At 24 h p.i.,
small NS1-positive cytoplasmic bodies were positive for
LAMP1, indicating co-localisation of lysosomes and NS1.
At 48 h p.i., larger NS1-positive cytoplasmic bodies were
commonly observed, and LAMP1 detection associated
with these larger, perinuclear bodies suggested that NS1
was localized within autolysosomes. These observations
indicated that NS1 protein expressed by NS1F-ELCmut,
was sequestered within cytoplasmic vesicles and
degraded via a lysosomal pathway. There was no evi-
dence of co-localisation of LAMP1 and NS1 protein
expressed by NS1F (not shown).
Autolysosomes are formed as part of the autophagy
pathway. The constitutive cellular protein LC3, is pro-
cessed proteolytically into LC3-II, which associates with
the autophagosomal membrane and is widely used as a
marker for autophagy. LC3-II was identified in NS1F-
infected Vero cells, but not NS1F-ELCmut-infected
Vero cells by 48 h p.i. (Figure 7). Therefore the associa-
tion of NS1 with lysosomes does not appear to involve
autophagy.
Discussion
It is well documented that both of the non-structural
proteins of RSV, NS1 and NS2, are type I IFN antago-
nists and target both the induction and signaling path-
ways. RSV mediates type I IFN signaling by degrading
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Figure 5 NS1 mutation affects the expression of IFN-b,a n dR S VNa n dN S 1m R N A s . A549 cells were infected with either NS1F, NS1F-
ELCmut, ΔNSI, or mock infected, and total RNA was extracted 24h p.i. The levels of mRNA encoding (a) IFN-b or (b) RSV N were measured by
RT-qPCR. (c) The ratio of IFN-b to RSV N mRNA was calculated. (d) The expression of NS1 mRNA was also measured by RT-qPCR. The level of
expression of each mRNA was calculated using the 2
-ΔΔCt formula in relation to mock-infected samples, and was normalised to b-actin. The ratio
of IFN-b/N mRNA was significantly higher in cells infected with NS1F-ELCmut and ΔNS1F compared to NS1F (* P < 0.01, ** P = 0.038).
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Page 8 of 12STAT2. Both NS1 and NS2 have been documented to
play a role in this response [17-20]. Elliot et al. (2007)
demonstrated that NS1 contains a consensus elongin C
binding domain, and can form an elongin C-cullin-SOCS
box-type E3 ubiquitin ligase. This may provide a mechan-
ism by which RSV targets STAT2 for proteosomal degra-
dation. The putative elongin C binding site within NS1, as
described by Elliot et al, (2007), is VxxLxxxCxxxK, which
differs in the fourth conserved residue from the consensus
motif of VxxLxxxCxxxA/I/L/V [23,24]. Due to the varia-
bility of the final amino acid, we chose to replace the 3
residues with full homology, V, L and C, with alanines (A),
as they are likely to be the most critical for function.
The resulting live rRSV NS1F-ELCmut was attenuated
in both type I IFN competent (A549) and -incompetent
(Vero) cells. This attenuation was similar to that
observed when NS1 was ablated entirely (ΔNS1) in
A549 cells, suggesting that mutation of the elongin C
binding domain affected viral growth nearly as much as
complete deletion of NS1. In fact, in A549 cells, muta-
tion of the elongin C binding region affected NS1
expression such that it was never detected by western
blot analysis or immunofluorescence. This suggests that
the attenuation of NS1F-ELCmut and ΔNS1’ were simi-
larly due to the significant reduction or absence of NS1
protein expression respectively. Both NS1F-ELCmut and
NS1/2 Overlay
GM130
EEA
PDI
LAMP1
24hpi
48hpi
LAMP1
Figure 6 The accumulation of mutated NS1 in cytoplasmic bodies. Mutated NS1 protein accumulated in cytoplasmic bodies that did not
co-localise with markers for cis -golgi (anti-GM130), ER (anti-PDI), or endosomes (anti-EEA-1), and did co-localise with a marker for lysosomes
(anti-LAMP1). Vero cells infected with NS1F-ELCmut were fixed 24 h p.i. and dual labelled with markers for the indicated organelles (green) and
anti-NS1/2 polyclonal antiserum (red). Overlay images were generated using Photoshop.
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Page 9 of 12ΔNS1 also induced similarly increased levels of IFN-b
mRNA, which correlated to viral attenuation and the
absence or significant reduction of NS1 protein. The
effect of deletion of NS1 on the replication of live rRSV
is well documented [6,7,21,22], as is the correlating
increase in the type I IFN response [7,17,18].
More insight into the effect of mutations within the
elongin C binding domain of NS1 was gained using
Vero cells. In these cells, the mutations in the elongin C
binding motif of NS1 did lead to NS1 degradation, but
the effect was delayed. Thus, NS1 was detected by
immunofluorescence up to 48 h p.i. The presence of
detectable NS1 early in infection and the slower rate of
NS1 degradation in Vero cells, correlated to moderate
attenuation of NS1F-ELCmut to levels between those of
NS1F and ΔNS1. It has been observed previously that
deletion of the NS proteins results in attenuation of
RSV in type I IFN-incompetent Vero cells [6,7].
In Vero cells infected with NS1F-ELCmut, NS1 was
degraded via a lysosomal-directed pathway. From 15 h
pi to 48 h pi, there was a shift in the location of NS1
from being both nuclear and diffusely cytoplasmic, to
being completely located within LAMP1-positive cyto-
plasmic bodies. The co-localisation of NS1 and LAMP1
suggested that NS1 was associated with lysosomes/
autolysosomes and that degradation of NS1 may occur
via autophagy. Autophagy involves the sequestration of
cytoplasmic cellular material into double-membrane
bound autophagosomes, which then fuse with lysosomes
to form autolysosomes for degradation of intracellular
materials [31]. Interactions between autophagy and viral
infection have been documented for many viruses [31].
However, little is documented concerning autophagy
during RSV infection. RSV-induced autophagy in den-
dritic cells has been shown to promote antiviral cytokine
responses [32]. During autophagy LC3 is activated and
recruited to the surface of autophagosomes. Activation
of LC3, as demonstrated here in NS1F-infected cells,
shows that RSV does induce autophagy in epithelial
cells. The accumulation of LAMP1-positive bodies in
the NS1F-ELCmut-infected cells suggested that autop-
hagy may have been induced. However, the lack of LC3
activation by NS1F-ELCmut by 48 h p.i. indicates that
the association of NS1 with lysosomes is not a conse-
quence of increased autophagy. The lack of activated
LC3 in NS1F-ELCmut-infected cells compared to NS1F-
infected cells is most likely correlated with the reduced
replication of the NS1F-ELCmut virus.
It is possible that the mutations introduced into the
elongin C binding motif of NS1 caused misfolding of
the protein leading to degradation. The tertiary struc-
ture is not known and therefore we were not able to
model these mutations to assist with protein engineer-
ing. There is one report of a method for purifying
rNS1-HIS
6 from E. coli and some information concern-
ing secondary structure of NS1 [33]. However, func-
tional regions have not yet been mapped and the
consequences of changes in secondary structure on NS1
function are not known. Protein structure prediction
using Protein Predict [34] indicated that this motif may
be a beta strand (weak prediction), and that the alanine
substitutions induce a predicted change to an alpha
helix (results not shown). Given the increased accuracy
of secondary predictions [35] it is reasonable to suspect
that the introduced mutations indeed changed the local
character of the secondary structure. However, whether
this resulted in global misfolding leading to degradation
is unknown.
Proteasomes and lysosomes represent the main pro-
teolytic pathways in mammalian cells. Misfolded pro-
teins are usually targeted for degradation via
proteosomes [36], as the proteosomal pathway requires
substrates to be unfolded to enter the narrow catalytic
core [37]. Lysosomes, in contrast, fuse to vesicles con-
taining proteins for degradation that are not necessarily
misfolded. Thus, the finding that degradation of NS1
occurred via a lysosome-driven pathway rather than a
proteosomal pathway in Vero cells suggests that the
mutations in NS1 may not have resulted in global
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Figure 7 The accumulation of mutated NS1 protein within
lysosomes does not involve autophagy. Vero cells were infected
with either NS1F, NS1F-ELCmut, or mock infected with media, and
cells were lysed in RIPA buffer 24 h and 48 h p.i. Equivalent
amounts of total protein were separated by SDS-PAGE and analysed
by Western blot. The active (LC3-II) and constitutive (LC3-I) forms of
LC3 were detected using anti-LC3B polyclonal antibody. NS1 was
detected using anti-FLAG monoclonal antibody. Representative of
three independent experiments.
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Page 10 of 12unfolding. Instead, it may be that the mutated NS1 pro-
tein became targeted for degradation as a consequence
of its failure to associate with the E3 ligase complex.
Although we attempted to investigate binding of NS1 to
elongin C, by using the FLAG tag to immunoprecipitate
NS1-associated proteins, the degradation of NS1 made
this difficult. Hence we cannot directly confirm or deny
binding of NS1 to elongin C.
T h ei n i t i a lp u r p o s eo fe n g i n eering mutations within
the elongin C biding domain of NS1 was to investigate
if NS1 did form an E3 ligase complex to degrade
STAT2 in a live virus infection, and to alter this func-
tion, such that STAT2 degradation was reduced during
RSV infection. Due to the rapid degradation of NS1 by
these mutations we were not able to demonstrate the
effect of these mutants on STAT2 within whole cell
populations. We did perform infection experiments in
A549 cells and identified isolated infected cells by
immunofluorescence 24 h after infection. We found that
STAT2 was degraded in NS1F-infected cells, as
expected, and not degraded in NS1F-ELCmut- and
ΔNS1-infected cells (additional file 1). This, however,
was most likely the result of a reduction or lack of NS1
expression, not the result of mutations within NS1.
There has been considerable effort over the last 30 years
to develop a vaccine for human RSV and currently live
attenuated RSVs may offer the best candidates [3]. As
deletion of NS1 or NS2 is attenuating and results in ele-
vated type I IFN-mediated antiviral responses each dele-
tion is being considered for inclusion in live-attenuated
vaccine candidates. Modification or deletion of specific
functional regions that inhibit the antiviral response may
provide improved mutants in which the interferon antago-
nist activities have been ablated while providing improved
growth. Alanine replacement of the conserved residues
within the elongin C binding domain of NS1, however,
resulted in attenuation similar to full deletion of NS1 in
A549 cells. It is therefore unlikely that this present set of
mutations will be useful in vaccine development. The data
presented here do suggest, however, that this region is cri-
tical to the survival of NS1 and may be a potential target
for antiviral agents. NS1 has proven to be a fruitful target
for anti-RSV therapy. RNAi using nanoparticle delivery of
siRNA targeting NS1 was used successfully to protect
against infection and to clear an existing RSV infection in
Fischer 344 rats [38]. A specific antiviral molecule that dis-
a b l e de l o n g i nCb i n d i n ga n dd e g r a d e dN S 1m a yp r o v e
effective for clearing RSV infection.
Conclusions
Mutations within the elongin C binding region of NS1
caused rapid degradation of NS1 protein, most likely via
sequestration in lysosomes. This degradation of NS1
caused a correlated attenuation of RSV replication and
an increase in the expression of IFN-b mRNA. Although
this mutation is over-attentuated for inclusion in a live
rRSV vaccine candidate, this region of NS1 is crucial for
the survival of NS1 protein and may be a target for
future antiviral compounds.
Additional material
Additional file 1: Immunofluorescence detection of STAT2 in
infected A549 cells. A549 cells were infected with NS1F, NS1F-ELCmut,
ΔNS1 or mock infected and fixed 24 h post-infection. STAT2 (green) and
RSV (red) were detected using specific antibodies. Nuclei were stained
with DAPI and overlay images generated using Photoshop. STAT2 was
degraded in NS1F-infected cells. STAT2 was not degraded in NS1F-
ELCmut or ΔNS1-infected cells. Arrows = infected cells.
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